The same holds true for absolute differences in the distribution of HF medications among patients in the EMB cohort, although such differences did not reach statistical significance likely due to the limited number of patients.
← all excerpts
Evaluation of phosphodiesterase 9A as a novel biomarker in heart failure with preserved ejection fraction.
1
—
—